MLTX
MoonLake Immunotherapeutics
$18.69
+5.30%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (77%)
Inst. Holders50 funds
Inst. Value$360.1M
Inst. Activity14 buys / 11 sells
Insider Activity0B / 7S
Insider Net $-$37.2M
Reddit Sentiment40° Cool
SEC Reports3
Press Releases2
Recent Activity
Jun 11, 2026
SEC
A cluster of 6 mega-passive institutional filers in MLTX shows a stark divergence: 3 small buyers (BofA, Wells Fargo, Mo
INST-CLUSTER — Impact 5/10
Jun 1, 2026
SEC
MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and Capacity Agreement with Vetter Pharma
8-K — Impact 2/10
May 11, 2026
Insider
Bodenstedt Matthias sold 13,653 shares
Chief Financial Officer @ $20.02 ($273.3K)
May 11, 2026
earnings_calendar
MLTX Q1 2026 Earnings Before Market Open — 2026-05-11
May 10, 2026
Press
MoonLake announced a successful final pre-BLA meeting with the FDA, aligning on submission plans and label strategy for
Impact 7/10
Apr 14, 2026
Insider
Bodenstedt Matthias sold 2,426 shares
Chief Financial Officer @ $19.56 ($47.5K)
Apr 13, 2026
Insider
Santos da Silva Jorge sold 51,873 shares
Chief Executive Officer @ $18.23 ($945.6K)
Apr 1, 2026
SEC
BVF Partners L.P., a 10% stockholder and affiliate of a director of MoonLake Immunotherapeutics, filed a Form 144 to not
144 — Impact 6/10
Price Targets
$27.62
+47.8% upside
Strong Buy
Current $18.69
Low $6.00
Median $30.00
High $46.00
13 analysts
$6.00
$46.00
Analyst Ratings
7Strong Buy
10Buy
3Hold
1Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 9, 2026 | BTIG | REITERATE | Buy → Buy |
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 12, 2026 | Needham | MAINTAIN | Buy → Buy |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 30, 2026 | BTIG | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.92 ▼ -1.9% | $-1.02 — $-0.81 | -5% YoY | 8 |
| Next Q | $-0.94 ▼ -1.3% | $-1.11 — $-0.75 | 14% YoY | 8 |
| Current FY | $-3.86 ▼ -3.8% | $-5.16 — $-3.25 | -9% YoY | 9 |
| Next FY | $-3.45 ▲ +4.9% | $-4.56 — $-2.90 | 11% YoY | 9 |
Latest Reports
BEARISH
INST-CLUSTER
5/10
A cluster of 6 mega-passive institutional filers in MLTX shows a stark divergence: 3 small buyers (BofA, Wells Fargo, Mo
Jun 11, 2026
NEUTRAL
8-K
2/10
MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and Capacity Agreement with Vetter Pharma
Jun 1, 2026
BULLISH
Press
7/10
MoonLake announced a successful final pre-BLA meeting with the FDA, aligning on submission plans and label strategy for
May 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| JANUS HENDERSON GROUP PLC | $64.3M | ADD |
| D. E. Shaw & | $44.6M | NEW |
| Point72 Asset Management, L.P. | $25.5M | ADD |
| CITADEL ADVISORS LLC | $24.7M | — |
| GOLDMAN SACHS GROUP INC | $21.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | Bodenstedt Matthias | SELL | $273.3K |
| Apr 14, 2026 | Bodenstedt Matthias | SELL | $47.5K |
| Apr 13, 2026 | Santos da | SELL | $945.6K |
| Apr 10, 2026 | Bodenstedt Matthias | SELL | $37.6K |
| Apr 10, 2026 | Santos da | SELL | $1.8M |
Reddit Sentiment
40°
Cool
Bearish
Neutral
Bullish
50 institutional holders with $360.1M total value (19,321,017 shares) as of 2026-Q1. Top holders: JANUS, D., Point72. Net buying activity: 14 institutions added/increased vs 11 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 3,451,628 | $64.3M | 17.9% | ADD +64.7% |
| 2 | D. E. Shaw & Co., Inc. | 2,390,661 | $44.6M | 12.4% | NEW |
| 3 | Point72 Asset Management, L.P. | 1,368,518 | $25.5M | 7.1% | ADD +77.2% |
| 4 | CITADEL ADVISORS LLC | 1,323,728 | $24.7M | 6.9% | — |
| 5 | GOLDMAN SACHS GROUP INC | 1,130,233 | $21.1M | 5.9% | — |
| 6 | TWO SIGMA INVESTMENTS, LP | 1,122,312 | $20.9M | 5.8% | ADD +72.8% |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 1,065,610 | $19.9M | 5.5% | TRIM -32.2% |
| 8 | BlackRock, Inc. | 1,021,851 | $19.0M | 5.3% | DOUBLED +256.6% |
| 9 | BANK OF AMERICA CORP /DE/ | 724,794 | $13.5M | 3.8% | DOUBLED +5255.8% |
| 10 | CITADEL ADVISORS LLC | 664,000 | $12.4M | 3.4% | — |
| 11 | MORGAN STANLEY | 614,482 | $11.5M | 3.2% | TRIM -41.2% |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 601,600 | $11.2M | 3.1% | — |
| 13 | Holocene Advisors, LP | 600,000 | $11.2M | 3.1% | NEW |
| 14 | Trexquant Investment LP | 495,336 | $9.2M | 2.6% | DOUBLED +168.7% |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 341,424 | $6.4M | 1.8% | — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 276,772 | $5.2M | 1.4% | DOUBLED +105.8% |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 265,600 | $5.0M | 1.4% | — |
| 18 | CONGRESS ASSET MANAGEMENT CO | 178,555 | $3.3M | 0.9% | DOUBLED +151.1% |
| 19 | FMR LLC | 143,559 | $2.7M | 0.7% | NEAR_EXIT -78.5% |
| 20 | TD ASSET MANAGEMENT INC | 142,706 | $2.7M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | ADD | 2,095,988 | 3,451,628 | +64.7% | $64.3M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 772,500 | 1,368,518 | +77.2% | $25.5M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 1,571,071 | 1,065,610 | -32.2% | $19.9M | 2026-Q1 |
| BlackRock, Inc. | DOUBLED | 286,593 | 1,021,851 | +256.6% | $19.0M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 13,533 | 724,794 | +5255.8% | $13.5M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 1,044,581 | 614,482 | -41.2% | $11.5M | 2026-Q1 |
| Holocene Advisors, LP | NEW | — | 600,000 | — | $11.2M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 184,319 | 495,336 | +168.7% | $9.2M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 134,472 | 276,772 | +105.8% | $5.2M | 2026-Q1 |
| CONGRESS ASSET MANAGEMENT CO | DOUBLED | 71,096 | 178,555 | +151.1% | $3.3M | 2026-Q1 |
| ExodusPoint Capital Management, LP | TRIM | 212,996 | 120,310 | -43.5% | $2.2M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 85,570 | 118,961 | +39.0% | $2.2M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | TRIM | 103,516 | 61,577 | -40.5% | $1.1M | 2026-Q1 |
| Mariner, LLC | DOUBLED | 20,159 | 44,950 | +123.0% | $837.8K | 2026-Q1 |
| Nuveen, LLC | NEAR_EXIT | 637,434 | 33,417 | -94.8% | $622.9K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 78,638 | 32,507 | -58.7% | $605.9K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | NEAR_EXIT | 183,552 | 26,307 | -85.7% | $490.4K | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 30,476 | 21,563 | -29.2% | $401.9K | 2026-Q1 |
| Legal & General Group Plc | ADD | 16,078 | 20,559 | +27.9% | $383.2K | 2026-Q1 |
| Jain Global LLC | NEAR_EXIT | 70,611 | 15,362 | -78.2% | $286.3K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 959,553 | 1,294,861 | +34.9% | $24.1K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | NEAR_EXIT | 61,948 | 923 | -98.5% | $17.2K | 2026-Q1 |
| Allworth Financial LP | ADD | 381 | 669 | +75.6% | $12.5K | 2026-Q1 |
| CWM, LLC | DOUBLED | 60 | 304 | +406.7% | $5.7K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 47 | 12 | -74.5% | $224.00 | 2026-Q1 |
3 unique insiders with 7 transactions. Net insider value: -$37.2M ($0.00 bought, $37.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | Bodenstedt Matthias | Chief Financial Officer | SELL | 13,653 | $20.02 | $273.3K |
| Apr 14, 2026 | Bodenstedt Matthias | Chief Financial Officer | SELL | 2,426 | $19.56 | $47.5K |
| Apr 13, 2026 | Santos da Silva Jorge | Chief Executive Officer | SELL | 51,873 | $18.23 | $945.6K |
| Apr 10, 2026 | Bodenstedt Matthias | Chief Financial Officer | SELL | 1,925 | $19.51 | $37.6K |
| Apr 10, 2026 | Santos da Silva Jorge | Chief Executive Officer | SELL | 98,127 | $18.41 | $1.8M |
| Apr 9, 2026 | Bodenstedt Matthias | Chief Financial Officer | SELL | 85,870 | $18.94 | $1.6M |
| Mar 31, 2026 | BVF PARTNERS L P/IL | Director | SELL | 1,932,354 | $16.79 | $32.4M |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 4.3/10.
BEARISH
INST-CLUSTER
5/10
A cluster of 6 mega-passive institutional filers in MLTX shows a stark divergence: 3 small buyers (B
Jun 11, 2026
NEUTRAL
8-K
2/10
MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and Capacity Agreement
Jun 1, 2026
BEARISH
144
6/10
BVF Partners L.P., a 10% stockholder and affiliate of a director of MoonLake Immunotherapeutics, fil
Apr 1, 2026
Current analyst consensus: Buy (77% buy). Based on 22 analysts: 7 strong buy, 10 buy, 3 hold, 1 sell, 1 strong sell.
Analyst Price Targets
$27.62 mean target
+47.8% upside
Strong Buy (1.87)
$6.00 Low
$46.00 High
| Metric | Value |
|---|---|
| Current Price | $18.69 |
| Target Low | $6.00 |
| Target Mean | $27.62 |
| Target Median | $30.00 |
| Target High | $46.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.87) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.92 | $-1.02 | $-0.81 | -5.4% | -1.9% | 1↑ 3↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-0.94 | $-1.11 | $-0.75 | 14.1% | -1.3% | 1↑ 2↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-3.86 | $-5.16 | $-3.25 | -9.3% | -3.8% | 2↑ 4↓ | $0.0B | 0.0% | 9 |
| Next FY 2027-12-31 |
$-3.45 | $-4.56 | $-2.90 | 10.7% | +4.9% | 5↑ 2↓ | $0.0B | 0.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.917 | |
| 7d ago | $-0.978 | +0.061 |
| 30d ago | $-0.899 | -0.017 |
| 60d ago | $-0.899 | -0.017 |
| 90d ago | $-0.940 | +0.023 |
9 analyst firms have rated this stock: 3 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 9, 2026 | BTIG | REITERATE | Buy | Buy |
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 30, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 23, 2026 | Wolfe Research | UPGRADE | Underperform | Outperform |
| Mar 19, 2026 | Rothschild & Co | UPGRADE | Neutral | Buy |
| Mar 11, 2026 | Clear Street | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 24, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 23, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 23, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Feb 9, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 3, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 15, 2026 | Goldman Sachs | DOWNGRADE | Neutral | Sell |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 9, 2026 | BTIG | UPGRADE | Neutral | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 10 | 3 | 1 | 1 | 77% | |
| May 1, 2026 | 8 | 10 | 3 | 1 | 1 | 78% | |
| Apr 1, 2026 | 8 | 10 | 3 | 1 | 1 | 78% | |
| Mar 1, 2026 | 7 | 9 | 4 | 1 | 2 | 70% | |
| Feb 1, 2026 | 7 | 9 | 5 | 1 | 2 | 67% | |
| Jan 1, 2026 | 11 | 11 | 2 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
40°
Cool
Bearish
Neutral
Bullish
1 mentions
0 bullish
1 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 11, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Managing protective long call options
▲ 5
💬 1
⚡ 0.5
Jun 9, 2026
Clinical Trial
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase Phase 3 — COMPLETED
Jun 9, 2026
Clinical Trial
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase Phase 3 — COMPLETED
May 11, 2026
earnings_calendar
MLTX Q1 2026 Earnings Before Market Open — 2026-05-11
May 10, 2026
announcement
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
<p align="justify"><b>ZUG, Switzerland, </b>May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage
May 7, 2026
earnings_calendar
MLTX Q1 2026 Earnings Before Market Open — 2026-05-07
Mar 28, 2026
fda
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
<p align="justify"><b>ZUG, Switzerland, </b>March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage bi
Feb 26, 2026
earnings_calendar
MLTX Q4 2025 Earnings Before Market Open — 2026-02-26